Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
KRYS

KRYS - Krystal Biotech Inc Stock Price, Fair Value and News

$182.69-6.57 (-3.47%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

KRYS RSI Chart

2024AprJul2030405060708090

KRYS Valuation

Market Cap

5.4B

Price/Earnings (Trailing)

51.33

Price/Sales (Trailing)

32.71

EV/EBITDA

265.72

Price/Free Cashflow

-238.93

KRYS Price/Sales (Trailing)

2024AprJul3040506070

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KRYS Fundamentals

KRYS Revenue

Revenue (TTM)

166.2M

Rev. Growth (Yr)

1.5K%

Rev. Growth (Qtr)

55.32%

20192020202120222023202460M80M100M120M140M160M

KRYS Earnings

Earnings (TTM)

105.9M

Earnings Growth (Yr)

146.88%

Earnings Growth (Qtr)

1.6K%

2018202020222024-150M-100M-50M050M100M

KRYS Price Action

Last 7 days

2.2%

Last 30 days

-1.7%

Last 90 days

9.3%

Trailing 12 Months

59.6%

KRYS Profitability

EBT Margin

7.76%

Return on Equity

12.63%

Return on Assets

11.54%

Free Cashflow Yield

-0.42%

KRYS Financial Health

Current Ratio

9.5

KRYS Investor Care

Shares Dilution (1Y)

2.63%

Diluted EPS (TTM)

3.81

KRYS Alerts

  • 2 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2024FebMarAprMayJun60M80M100M120M140M160M
Net sales
YearQ1Q2Q3Q4
2024108.5M166.2M00
202300050.7M
20180000
KRYS
Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
 CEO
 WEBSITEkrystalbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES210

Krystal Biotech Inc Frequently Asked Questions


What is the ticker symbol for Krystal Biotech Inc? What does KRYS stand for in stocks?

KRYS is the stock ticker symbol of Krystal Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Krystal Biotech Inc (KRYS)?

As of Tue Sep 17 2024, market cap of Krystal Biotech Inc is 5.44 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KRYS stock?

You can check KRYS's fair value in chart for subscribers.

Is Krystal Biotech Inc a good stock to buy?

The fair value guage provides a quick view whether KRYS is over valued or under valued. Whether Krystal Biotech Inc is cheap or expensive depends on the assumptions which impact Krystal Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KRYS.

What is Krystal Biotech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Sep 17 2024, KRYS's PE ratio (Price to Earnings) is 51.33 and Price to Sales (PS) ratio is 32.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRYS PE ratio will change depending on the future growth rate expectations of investors.